Tag Archives: Urogen Pharma Ltd

Stifel Nicolaus Keeps a Buy Rating on Urogen Pharma Ltd (URGN)

Stifel Nicolaus analyst Derek Archila reiterated a Buy rating on Urogen Pharma Ltd (URGN – Research Report) yesterday and set a price target of $61. The company’s shares closed last Monday at $32.65, close to its 52-week low of $29.73.

Urogen Pharma Ltd (URGN) Received its Third Buy in a Row

After H.C. Wainwright and Oppenheimer gave Urogen Pharma Ltd (NASDAQ: URGN) a Buy rating last month, the company received another Buy, this time from Stifel Nicolaus. Analyst Derek Archila reiterated a Buy rating on Urogen Pharma Ltd today and set

Cowen & Co. Thinks Urogen Pharma Ltd’s Stock is Going to Recover

In a report released today, Boris Peaker from Cowen & Co. maintained a Buy rating on Urogen Pharma Ltd (URGN – Research Report). The company’s shares opened today at $36.14, close to its 52-week low of $34.61. According to TipRanks.com,

Analysts Offer Insights on Healthcare Companies: Urogen Pharma Ltd (NASDAQ: URGN), Pfizer (NYSE: PFE) and Bausch Health Companies Inc (NYSE: BHC)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Urogen Pharma Ltd (URGN – Research Report), Pfizer (PFE – Research Report) and Bausch Health Companies Inc (BHC – Research Report) with

Oppenheimer Thinks Urogen Pharma Ltd’s Stock is Going to Recover

Oppenheimer analyst Leland Gershell maintained a Buy rating on Urogen Pharma Ltd (URGN – Research Report) today. The company’s shares opened today at $38.13, close to its 52-week low of $34.61. According to TipRanks.com, Gershell is a 2-star analyst with

Stifel Nicolaus Thinks Urogen Pharma Ltd’s Stock is Going to Recover

In a report released today, Derek Archila from Stifel Nicolaus reiterated a Buy rating on Urogen Pharma Ltd (URGN – Research Report), with a price target of $63. The company’s shares opened today at $39.66, close to its 52-week low